Results 51 to 60 of about 68,452 (304)

Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells. [PDF]

, 2019
Tumor cells harboring stem-like/cancer stem cell (CSC) properties have been identified and isolated from numerous hematological and solid malignancies.
Ames, Erik, Bouzid, Lyes A, Canter, Robert J, Darrow, Morgan A, Grossenbacher, Steven K, Judge, Sean J, Luna, Jesus I, Murphy, William J, Sturgill, Ian R   +8 more
core   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

Journal for ImmunoTherapy of Cancer, 2017
Chimeric antigen receptor (CAR) T-cell therapy represents a revolutionary treatment for haematological malignancies (i.e. B-ALL). However, the success of this type of treatment has not yet been achieved in solid tumors.
Irene Scarfò, Marcela V. Maus
doaj   +1 more source

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. [PDF]

, 2018
Malignant gliomas carry a dismal prognosis. Conventional treatment using chemo- and radiotherapy has limited efficacy with adverse events. Therapy with genetically engineered T-cells, such as chimeric antigen receptor (CAR) T-cells, may represent a ...
Almeida, Neil D, Chuntova, Pavlina, Downey, Kira M, Hegde, Bindu, Okada, Hideho   +4 more
core  

Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies. [PDF]

, 2015
Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists.
Biassoni, Biron, Björklund, Brodin, Bryceson, Burns, Campbell, Cooley, Cooper, Cooper, Curti, Davies, Di Santo, Di Santo, Farag, Fehniger, Fogler, Foley, Freud, Gasser, Gilfillan, Grimm, Guethlein, Herberman, Huntington, Joncker, Kiessling, Killig, King, Kröger, Lajoie, Lanier, Leong, Ljunggren, Lowe, Lundqvist, Mancusi, McQueen, Miller, Moretta, Moretta, Moretta, Nguyen, Oevermann, Ouyang, Perussia, Phillips, Romagnani, Romee, Rosenberg, Rosenberg, Rosenberg, Ruggeri, Santoni, Stabile, Stabile, Stern, Stringaris, Thielens, Torelli, Trinchieri, Trinchieri, Vago, Valés-Gómez, Venstrom, Vivier, Whitelaw, Zorn   +67 more
core   +1 more source

Adoptive immunotherapy against ovarian cancer [PDF]

Journal of Ovarian Research, 2016
The standard front-line therapy for epithelial ovarian cancer (EOC) is combination of debulking surgery and platinum-based chemotherapy. Nevertheless, the majority of patients experience disease recurrence. Although extensive efforts to find new therapeutic options, cancer cells invariably develop drug resistance and disease progression.
MITTICA, Gloria, Capellero, Sonia, GENTA, SOFIA, Cagnazzo, Celeste, AGLIETTA, Massimo, SANGIOLO, Dario, VALABREGA, Giorgio   +6 more
openaire   +2 more sources

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

Molecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor, Julio Celis, Ulrik Ringborg   +2 more
wiley   +1 more source

Long-term survival after immunotherapy and targeted therapy without chemotherapy in an elderly patient with HER2-positive gastroesophageal junction cancer: A case report

Human Vaccines & Immunotherapeutics, 2022
A 74-yr-old man underwent thoracic laparoscopy combined with radical gastrectomy, and the postoperative pathological diagnosis was esophageal and gastric cardia cancer pT3N1M0, pStage IIB. Immunohistochemical staining for HER2 (3+) and PD-L1 (
Wei-Ling Li, Ying Zhang, Xiao-Ling Zhang, Yun-Yi Du, Wen-Qing Hu, Jun Zhao   +5 more
doaj   +1 more source

Review of precision cancer medicine: Evolution of the treatment paradigm. [PDF]

, 2020
In recent years, biotechnological breakthroughs have led to identification of complex and unique biologic features associated with carcinogenesis. Tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify ...
Fountzilas, Elena, Kurzrock, Razelle, Nikanjam, Mina, Tsimberidou, Apostolia M   +3 more
core   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

Molecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source